Neurocompute scores biomedical literature, surfaces overlooked patterns, and turns Parkinson’s research into a living discovery terminal.
D grade · PMID 41976920
View analysis →D grade · PMID 41909415
View analysis →D grade · PMID 42041287
View analysis →D grade · PMID 41948675
View analysis →D grade · PMID 41910477
View analysis →D grade · PMID 41946557
View analysis →D grade · PMID 41902432
View analysis →D grade · PMID 41982421
View analysis →D grade · PMID 42028943
View analysis →D grade · PMID 42031673
View analysis →Large cross-sectional analysis of 17,105 older adults across 27 countries showing that physical inactivity, social participation, and intellectual activities have differential associations with specific cognitive domains across healthy, dementia, Parkinson's disease, and stroke groups, with…
While it provides little mechanistic or pharmacological insight for Parkinson's therapeutic discovery, the study supports targeting physical activity and cognitive engagement as adjunctive, non‑drug strategies and informs selection of cognitive endpoints and lifestyle covariates for PD clinical…
A case report of primary CNS lymphoma presenting as rapidly progressive, right-predominant parkinsonism initially misdiagnosed as progressive supranuclear palsy, with diagnosis confirmed by repeat MRI and biopsy and treated with corticosteroids.
Low direct value for Parkinson's therapeutic discovery (no PD mechanisms or targets), but clinically important as a potentially reversible parkinsonism mimic, emphasizing thorough workup and repeat imaging in atypical or rapidly progressing cases.
Qualitative study identifying seven barriers and enablers to cognitive assessment in Parkinson's disease and recommending implementation strategies (clinician education, resource allocation, support/feedback, and patient advocacy) to facilitate uptake of the 'PDCogniCare' program.
The work is valuable for improving early cognitive screening and care pathways in PD—which can affect patient management and trial recruitment—but offers limited direct mechanistic or therapeutic discovery insights for drug development.
Retrospective analysis showing that visual swallowing instructions (charts/handouts) and living with family improve patient compliance with dysphagia strategies and are associated with maintained or improved dysphagia-related quality of life in PD.
This paper has limited direct impact on Parkinson's therapeutic discovery (no mechanistic or drug-target insights) but is useful for clinical management, improving patient QOL and adherence—factors that can indirectly affect outcomes and trial conduct in PD research.
In a behavioral study of 24 prodromal/mild DLB patients vs 24 matched controls, patients showed impaired facial emotion recognition and higher alexithymia, depression, and anxiety scores.
While not mechanistic, the identification of early emotional disturbances in prodromal DLB could inform clinical recognition of synuclein-related prodromal states and guide early symptomatic management or stratification in PD-spectrum research.
In a cross-sectional substudy of 211 people with parkinsonism enrolled in the PRIME-UK trial, 25% had treatment escalation plans (45% created during emergency admissions), 100 had lasting power of attorney, and greater disease severity, frailty, and comorbidity were associated with having a plan.
Highlights important gaps and predictors in advance care planning for people with parkinsonism—useful for clinical care and service design but of limited direct relevance to therapeutic discovery or mechanistic research.
Retrospective mixed-methods evaluation found that a single-session group-based advance care planning workshop for people with Parkinson's spectrum disorders increased understanding and comfort with ACP, raised readiness to appoint a power of attorney, and led to new ACP discussions and actions…
This work is useful for improving patient engagement, care planning, and trial readiness in clinical settings but provides minimal mechanistic, biomarker, or therapeutic-discovery information for Parkinson's drug development.
This systematic review reports mostly preclinical evidence that subanesthetic ketamine can improve cognition in animal models of neurological injury (including some PD models) via glutamatergic modulation, synaptogenesis, and anti-inflammatory effects, but human data are extremely limited and…
Mechanistically relevant pathways (NMDA signaling, synaptogenesis, neuroinflammation) could make ketamine a candidate for repurposing to treat cognitive symptoms in Parkinson’s, but the paucity of human data and safety/efficacy concerns limit immediate translational value and require controlled…
This paper reviews two recent studies: one identifying FAM171A2 as a receptor mediating cell-to-cell propagation of misfolded α‑synuclein, and another showing that variable positioning of α‑synuclein terminal regions influences pathogenicity and spread, suggesting that blocking the receptor or…
By pointing to a potentially druggable receptor (FAM171A2) and to structural epitope-targeting strategies that could reduce α‑synuclein spread, the work provides concrete, translatable therapeutic leads for slowing Parkinson’s disease progression.
Transcriptomic analysis of iPSC-derived dopaminergic neurons from LRRK2 and Parkin mutation carriers reveals a convergent signature of reduced developmental/Wnt-β-catenin and axon-growth programs, increased synaptic maturation markers, and upregulation of the TRAIL apoptotic pathway.
Highlights shared, targetable pathways (Wnt/β-catenin suppression, impaired structural/axon growth, TRAIL-mediated apoptosis) across hereditary PD forms that generate actionable hypotheses for neuroprotective interventions and biomarker development, though findings are limited to in vitro iPSC…
Using LC3-Rosella live imaging in iPSC-derived neurons and midbrain organoids from SNCA triplication PD patients, the study demonstrates early and progressive autophagy/autolysosome dysfunction that temporally correlates with increased total and pS129 α‑synuclein and dopaminergic neuronal…
Provides human-relevant, temporally resolved evidence linking impaired autophagy to α‑synuclein pathology and neuronal loss, supporting autophagy/lysosomal pathways as actionable targets and these organoid models for therapeutic screening.
In a propensity-matched PPMI cohort, LRRK2-PD patients who are alpha-synuclein SAA-positive had lower baseline motor scores and dopaminergic deficit than S+ sporadic PD, but showed similar 4-year clinical progression trajectories.
Shows that alpha-synuclein SAA stratification identifies a biologically relevant subgroup and indicates S+ LRRK2-PD progresses similarly to S+ sporadic PD, informing biomarker-driven trial design, patient selection, and outcome measures for LRRK2- or alpha-synuclein-targeted therapeutics.
In a French multicenter retrospective cohort of 50 mostly MSA-P patients with partial dopaminergic responsiveness, continuous subcutaneous apomorphine infusion yielded short‑term (6-month) improvement in motor fluctuations with generally acceptable tolerability.
The study supports symptomatic repurposing of apomorphine for selected MSA patients—useful for clinical management and designing symptomatic treatment trials—but provides limited mechanistic or disease‑modifying insight relevant to Parkinson's therapeutic discovery.
Single-unit recordings from the human substantia nigra in Parkinson’s patients show that putative dopaminergic neurons have elevated firing during reward expectation following positive outcomes, and this activity predicts faster subsequent reaction times.
Provides human physiological evidence linking reward history to dopaminergic signaling and behavioral vigor, offering a potential biomarker of residual DA function and a rationale for tailoring neuromodulation or behavioral interventions in PD.
Develops validated, eco-friendly spectrophotometric techniques to selectively quantify entacapone in the presence of levodopa and carbidopa in pharmaceutical formulations without separation.
Provides practical, sustainable assays for routine quality control and manufacturing of entacapone-containing products but offers little mechanistic, translational, or therapeutic-discovery insight for Parkinson's disease research.
Alpha-synuclein overexpression in rat substantia nigra reduces VGF-derived NAPP-129 and TLQP-62 in the SN and plasma (but not striatum), suggesting these peptides reflect alpha-syn pathology.
Identifies circulating VGF-derived peptides as potential early, disease-specific biomarkers linked to alpha-synuclein pathology with translational value for PD diagnosis or trials, though human validation and mechanistic/therapeutic follow-up are needed.
Using dual-polarity MALDI-MSI in an AAV-α-synuclein mouse model, the study maps region-specific lipid changes in the nigrostriatal pathway—altered gangliosides, sphingomyelins and sulfatides in substantia nigra/striatum, a shift from PUFA- to saturated/monounsaturated-containing…
By directly linking α-synuclein overexpression to spatially resolved alterations in sphingolipid and phospholipid metabolism (including lipid oxidation and ganglioside/sulfatide changes), the work highlights actionable lipid pathways and potential biomarkers that could be targeted or monitored in…
This study demonstrates that H2O2-mediated oxidative modification of the neuronal motor KIF1A reduces its processive motility in vitro, creates disulfide-linked multimers, and is partly reversible with reducing agents or cysteine substitutions.
By linking oxidative stress to impaired axonal transport via direct damage to a kinesin motor, the work provides a mechanistic, targetable connection between redox pathology and neurodegeneration that could motivate redox-modulating or motor-stabilizing therapeutic strategies for Parkinson's…
The authors report LD-b-PBTA, a lipid droplet–selective, highly retained fluorescent probe that enables long-term (up to 72 h) labeling and in vivo/ex vivo detection of pathological lipid droplet accumulation in dopaminergic neurons in Parkinson's disease models.
This tool enables longitudinal, in vivo visualization of a metabolic/pathology biomarker (lipid droplets) in the substantia nigra, facilitating biomarker development, mechanistic study of lipid-related PD pathology, and screening of interventions that target lipid metabolism or downstream…
Using a Drosophila rotenone-feeding model of sporadic PD, the study reports sex-specific gene expression changes across adult life stages and identifies pathways altered by toxin exposure that could serve as early transcriptional biomarkers.
By revealing sex-biased molecular responses to a mitochondrial toxin (rotenone), the work highlights candidate pathways/biomarkers and underscores the importance of sex as a variable for translational biomarker discovery and sex-aware therapeutic strategies in PD research.
